Cue Biopharma’s (NASDAQ:CUE) quiet period will expire on Monday, February 12th. Cue Biopharma had issued 8,820,710 shares in its public offering on January 2nd. The total size of the offering was $66,155,325 based on an initial share price of $7.50. During the company’s quiet period, insiders and underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Shares of Cue Biopharma (CUE) opened at $14.16 on Friday. Cue Biopharma has a 12-month low of $11.10 and a 12-month high of $16.56. The firm has a market cap of $235.63 and a P/E ratio of -15.06.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/02/08/cue-biopharma-incs-quiet-period-to-expire-on-february-12th-nasdaqcue.html.

About Cue Biopharma

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program.

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.